Comparing BR Biopharma (BRBI) and Its Competitors

BR Biopharma (NASDAQ:BRBI) is one of 1,748 public companies in the “Capital Markets” industry, but how does it weigh in compared to its peers? We will compare BR Biopharma to related businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, dividends, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations for BR Biopharma and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BR Biopharma	1	0	0	0	1.00
BR Biopharma Competitors	5371	19705	21889	613	2.37

As a group, “Capital Markets” companies have a potential upside of 26.13%. Given BR Biopharma’s peers stronger consensus rating and higher possible upside, analysts plainly believe BR Biopharma has less favorable growth aspects than its peers.

Dividends

BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.8%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Capital Markets” companies pay a dividend yield of 3.2% and pay out 30.8% of their earnings in the form of a dividend.

Profitability

This table compares BR Biopharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BR Biopharma	N/A	N/A	N/A
BR Biopharma Competitors	266.99%	77.99%	3.52%

Valuation and Earnings

This table compares BR Biopharma and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BR Biopharma	$2.23 billion	$31.36 million	139.24
BR Biopharma Competitors	$2.39 billion	$396.21 million	8.75

BR Biopharma’s peers have higher revenue and earnings than BR Biopharma. BR Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

30.6% of shares of all “Capital Markets” companies are owned by institutional investors. 12.9% of shares of all “Capital Markets” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

BR Biopharma peers beat BR Biopharma on 12 of the 14 factors compared.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.